All News
EULAR 2018 - Podcast from Day 3
This EULAR 2018 Podcast is a compilation of audio clips from EULAR in Amsterdam.
You can also listen on iTunes, Soundcloud or Stitcher.
Read Article
High Biologic Blood Levels Increases the Risk of Infections in RA
A big concern of most is the risk of infection with use of tumour necrosis factor inhibitor (TNFi) and biologic drugs. While studied in both trials and in post-marketing studies, it is unknown if infection risk is dose-dependent.
Read ArticleThe RheumNow Week in Review – EULAR18 Abbreviated (6.15.18)
We're crazy busy at EULAR all week. Instead of this review, we recommend that you tune into our multiple podcasts from experts and faculty attending EULAR 2018 in Amsterdam. You can find these on iTunes, SoundCloud or Stitcher.
Read ArticleChanging my Mind at EULAR
Each year I attend I hope that I’m going to come across something that changes my practice and this year, I think I may have struck gold at a session on Giant Cell arteritis at EULAR in Amsterdam.
Read ArticleUpdate on Osteoporosis
This session was an update on the management of osteoporosis given by Professor Christian Roux from France.
Read ArticleIncreased Risk of Infection in Psoriasis and Psoriatic Arthritis
As we gather more knowledge about psoriatic arthritis ( PsA) and psoriasis (PSO) over time, and achieve better outcomes with new therapies, more questions arise about quality of life, survival and comorbidities in PsA and PSO.
Read ArticleEULAR 2018 - Day 2 Report
Highlights from Day 2 of the EULAR meeting in Amsterdam include high MBDA scores in ACPA negative RA predicts remission; characterization of difficult RA; and gender differences in psoriatic responses to TNF inhibitors.
Read ArticleEULAR 2018 - Podcast from Day 1 & 2
This EULAR 2018 Podcast is a compilation of audio clips from EULAR in Amsterdam.
Read ArticleCardiovascular Risk Factors in Psoriasis, PsA and Seronegative SpA
Not a surprise to anyone anymore, increased risk of cardiovascular disease poses a danger of significant morbidity and mortality in patients underlying inflammatory arthritides.
Read ArticleBiosimilar Data at #EULAR2018
Biosimilars are here, and more are being registered all the time, so I was really interested in the biosimilar data at the meeting.
Abbvie Highlights Upadacitinib Trials at EULAR18
Abbvie press releases feature the results from 3 new trials to be presented during the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam from three Phase 3 trials evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderat
Read ArticleEULAR 2018 - Day 1 Report
Highlights from the first day at EULAR include: canakinumab prevents acute gout; AS uveitis benefits from most TNFi; MRI does not improve T2Tor X-ray outcomes; baracitinib wins in SLE - maybe?; new lupus criteria; and lost survival in RA. Here's the RheumNow recap.
Read ArticleCancer Therapies Inducing Immune-Related Adverse Events (irAEs)
Recent shifts in the cancer treatment paradigm towards immune therapies has led to wide implementation of the novel immune check point inhibitors (ICI) in the treatment of multiple types of advanced cancer.
Read ArticleVedolizumab Implicated in Exacerbations of SpA in IBD Patients
Beloved by gastroenterologist for treatment of inflammatory bowel disease (IBD), α4β7 integrin receptor vedolizumab (VDZ) has probably caught attention of many rheumatologist since the time it entered the market; largely for what it won't do for inflammatory arthritis.
Read ArticleJAK Inhibition in Autoinflammatory Syndromes Interferonopathies
While many autoinflammatory syndromes are driven and managed with select inhibition of IL-1, IL-18 or IL-6, a subset are driven by type I interferon and are referred to as interferonopathies. These monogenic IFN–mediated disorders present in infancy with fevers, systemic inflammation, an IFN response gene signature, inflammatory organ damage, and high mortality.
Read ArticleTNF Inhibitors Don't Increase Cancer Risk in Children
While the risk of neoplasia with tumour necrosis factor inhibitor (TNFi) use has been largely nullified in most inflammatory disorders, this risk in children is less certain. However a recent study shows no risk of increased cancer in children treated with TNFi for juvenile idiopathic arthritis (JIA), pediatric inflammatory bowel disease (pIBD) and pediatric plaque psoriasis (pPsO).
Read ArticleThe Microbiome and Lupus Connection Reviewed
In the current issue of the New England Journal of Medicine, Drs. James Rosenbaum and Gregg Silverstein review the pathogenesis of systemic lupus erythematosus (SLE) from the viewpoint of a dysbiolsis.
Read ArticleRisk of Psoriasis Complicating TNF Inhibitor Therapy
A population-based study of claims data from Korea shows that among inflammatory bowel disease (IBD) patients receiving tumour necrosis factor inhibitors (TNFi) there is a 3.7 per 100 patient-year risk of paradoxically developing psoriasis - a rate that is roughly 3-fold higher than risk in TNFi-naive IBD patients.
Read ArticleCanada Closer to Marijuana Approval
Reuters reports that Canada’s Senate on Thursday voted to legalize recreational marijuana, clearing a major hurdle that puts the country on track to become the first Group of Seven nation to permit national use of the drug.
Read ArticleThe RheumNow Week in Review – Baricitinib Splash (6.7.18)
Dr. Jack Cush discusses the past week's news and journal articles featured on RheumNow.com - including reports on advance practice clinicians, baricitinib, gout, disease activity, hypomagnesemia and upadacitinib.
Read Article